Clinical Rheumatology

, Volume 28, Issue 8, pp 985–988

Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab

Brief Report


To analyse the effectiveness and safety of adalimumab in a group of patients with juvenile idiopathic arthritis (JIA) who had failed treatment with etanercept and/or infliximab in a single paediatric rheumatology clinic. Patients with JIA with active polyarthritis refractory to metotrexate (MTX) (≥20 mg/m2/week) for at least 3 months and to etanercept (up to 1 mg/kg twice weekly) and/or infliximab (up to 10 mg/kg every 4 weeks) for at least 6 months were included. All patients received adalimumab 24 mg/m2/week concomitantly with MTX 7.5–10 mg/week. Evaluation of efficacy included improvement as defined by the ACR paediatric 30 criteria, 50% and 70% improvement and remission. Six patients were included. Three patients met improvement criteria; 50% and 70% improvement occurred in two children. Improvement was sustained for 12, 24 and 36 months, respectively. Remission occurred in one patient. Adalimumab was discontinued due to lack of efficacy in three patients. No side effects were observed. Adalimumab appears to be effective and safe in patients with JIA refractory to other anti-TNF agents. Further controlled studies are needed in order to assess efficacy of adalimumab in children with refractory JIA.


Adalimumab Etanercept Infliximab Juvenile idiopathic arthritis 


  1. 1.
    Schneider R, Passo MH (2002) Juvenile rheumatoid arthritis. Rheum Dis Clin North Am 28:503–530PubMedCrossRefGoogle Scholar
  2. 2.
    De Benedetti F, Ravelli A, Martini A (1997) Cytokines in juvenile rheumatoid arthritis. Curr Opin Rheumatol 9:428–433PubMedCrossRefGoogle Scholar
  3. 3.
    Wilkinson N, Jackson G, Gardner-Medwin J (2003) Biologic therapies for juvenile arthritis. Arch Dis Child 88:168–191CrossRefGoogle Scholar
  4. 4.
    Ruperto N, Murray K, Gerloni V, Wulffraat N, Oliveira S, Falcini F et al (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who fail to response to standard doses of methotrexate. Arthritis Rheum 50:2191–2201PubMedCrossRefGoogle Scholar
  5. 5.
    Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein L et al (2006) Long term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 54:1987–1994PubMedCrossRefGoogle Scholar
  6. 6.
    Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M et al (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48:1093–1101PubMedCrossRefGoogle Scholar
  7. 7.
    Lahdenne P, Vähäsalo P, Honkanen V (2003) Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62:245–247PubMedCrossRefGoogle Scholar
  8. 8.
    Favalli E, Arreghini M, Arnoldi C, Panni B, Marchesoni A, Tossi S et al (2004) Anti-tumor necrosis factor α switching in rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum 51:299–304CrossRefGoogle Scholar
  9. 9.
    Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418–426PubMedCrossRefGoogle Scholar
  10. 10.
    Moroldo MB, DeCunto C, Hubscher O, Liberatore D, Palermo R, Russo R et al (1998) Cross-cultural adaptation and validation of an Argentine-Spanish version of the Stanford Childhood Health Assessment Questionnaire (CHAQ). Arthritis Care Res 11:382–390PubMedCrossRefGoogle Scholar
  11. 11.
    Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40:1202–1209PubMedGoogle Scholar
  12. 12.
    Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH (2005) Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 52:3554–3562PubMedCrossRefGoogle Scholar
  13. 13.
    Lovell D, Giannini E, Reiff A, Cawkwell G, Silverman ED, Nocton JJ et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342:763–769PubMedCrossRefGoogle Scholar
  14. 14.
    Katsicas MM, Russo RA (2005) Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. Clin Exp Rheumatol 23:545–548PubMedGoogle Scholar
  15. 15.
    Lovell D, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcová D, Mouy R et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810–820PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2009

Authors and Affiliations

  1. 1.Service of Immunology/RheumatologyHospital de Pediatría “Prof. Dr. Juan P. Garrahan”Buenos AiresArgentina

Personalised recommendations